These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7168451)

  • 21. Evaluating antitrust risk in joint provider negotiations with payors.
    Leonard EJ
    Med Staff Couns; 1992; 6(1):41-7. PubMed ID: 10115450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician agreements to control medical prepayment plans: Federal Trade Commission. Adoption and publication of enforcement policy with respect to physician agreements to control medical prepayment plans.
    Fed Regist; 1981 Oct; 46(192):48982-92. PubMed ID: 10252959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Supreme Court, antitrust and the health care field.
    Health Law Vigil; 1982 Oct; 5(22):1-14. PubMed ID: 10257142
    [No Abstract]   [Full Text] [Related]  

  • 24. Understanding antitrust: focus on the relevant market.
    Enders RJ
    Healthc Financ Manage; 1986 Feb; 40(2):25-32. PubMed ID: 10275004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPOs and the antitrust laws.
    Stromberg RE; Duncheon MA; Goldman JS
    Hospitals; 1983 Oct; 57(20):65-70. PubMed ID: 6618473
    [No Abstract]   [Full Text] [Related]  

  • 26. U.S. Supreme Court rejects case-by-case antitrust analysis in Maricopa.
    McCann RW
    Health Law Vigil; 1982 Jun; 5(13):1-4. PubMed ID: 10256005
    [No Abstract]   [Full Text] [Related]  

  • 27. A competitive analysis of most favored nations clauses in contracts between health care providers and insurers.
    Celnicker A
    Spec Law Dig Health Care (Mon); 1991 Dec; (154):7-36. PubMed ID: 10115476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic analysis in health care antitrust.
    Vita MG; Langenfeld J; Pautler P; Miller L
    J Contemp Health Law Policy; 1991; 7():73-115. PubMed ID: 10111250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Court: Indiana Blues may adopt PPO plan without antitrust scrutiny.
    Allen HS; Rothschild IS
    Health Law Vigil; 1986 Apr; 9(8):4-5. PubMed ID: 10278389
    [No Abstract]   [Full Text] [Related]  

  • 30. Monopolies, Maricopa, and marketing: a case study.
    Perkins J; Mercer A; McClary C
    Hosp Health Serv Adm; 1986; 31(4):34-44. PubMed ID: 10277339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preferred provider organizations and antitrust policy: some recent issues.
    Costillo LB
    Health Matrix; 1986; 4(2):22-5. PubMed ID: 10278618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Planning PPOs to minimize antitrust risk.
    Clanton DA
    Hospitals; 1985 Mar; 59(5):96, 98. PubMed ID: 3972373
    [No Abstract]   [Full Text] [Related]  

  • 33. Legally speaking: Federal Trade Commission issues positive advisory opinions on antitrust implications of clinical integration.
    Wright R
    J Ark Med Soc; 2009 Oct; 106(4):88-9. PubMed ID: 19813398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health care planning is granted antitrust immunity.
    Bolze RS
    Health Prog; 1985 Nov; 66(9):34-5, 62. PubMed ID: 10274589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A practical guide to health care antitrust issues.
    Kopit WG; Barnes CE; Latorre L
    Trustee; 1986 May; 39(5):16-8. PubMed ID: 10276551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Court decisions expand industry's antitrust exposure.
    Waxman JM
    Rev Fed Am Hosp; 1982; 15(5):52-3. PubMed ID: 10256503
    [No Abstract]   [Full Text] [Related]  

  • 37. Minimizing antitrust risks of Blue Cross and Blue Shield plans.
    Steele CJ
    J Contemp Health Law Policy; 1988; 4():227-72. PubMed ID: 10288422
    [No Abstract]   [Full Text] [Related]  

  • 38. Historic Supreme Court decisions make clear that health care area is subject to antitrust scrutiny.
    Employee Benefit Plan Rev; 1982 Aug; 37(2):8-10. PubMed ID: 10259394
    [No Abstract]   [Full Text] [Related]  

  • 39. Preferred provider organizations: an antitrust warning.
    Sandler AL
    Group Pract J; 1987; 36(6):41-2, 44. PubMed ID: 10284861
    [No Abstract]   [Full Text] [Related]  

  • 40. Perspectives. PPOs face antitrust problems.
    Wash Rep Med Health; 1984 Nov; 38(44):suppl 4p. PubMed ID: 10268861
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.